Compositions and methods for enhancing drug delivery across and into epithelial tissues
First Claim
1. A method for enhancing delivery of a compound into and across one or more layers of an animal epithelial or endothelial tissue, the method comprising:
- contacting the endothelial or epithelial tissue with a conjugate that comprises the compound attached to a delivery-enhancing transporter by a linker, wherein the delivery-enhancing transporter comprises sufficient guanidino or amidino moieties to increase delivery of the conjugate into and across one or more intact epithelial or endothelial tissue layers compared to delivery of the compound in the absence of the delivery-enhancing transporter; and
the conjugate has a structure selected from the group consisting of structures 3, 4, 5 and 6, as follows;
wherein;
R1—
X comprises the compound;
X is a functional group on the compound to which the linker is attached;
Y is N or CH;
R2 is hydrogen, alkyl, aryl, acyl, or allyl;
R3 comprises the delivery-enhancing transporter;
R4 is unsubstituted O, substituted N or C or substituted or unsubstituted S;
R5 is OH, SH or NHR6;
R6 is hydrogen, alkyl, aryl, acyl or allyl;
k and m are each independently selected from 1 and 2;
n is 1 to 10; and
Ar is an aryl group having the attached radicals arranged in an ortho or para configuration, which aryl group can be substituted or unsubstituted.
3 Assignments
0 Petitions
Accused Products
Abstract
This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.
-
Citations
134 Claims
-
1. A method for enhancing delivery of a compound into and across one or more layers of an animal epithelial or endothelial tissue, the method comprising:
-
contacting the endothelial or epithelial tissue with a conjugate that comprises the compound attached to a delivery-enhancing transporter by a linker, wherein the delivery-enhancing transporter comprises sufficient guanidino or amidino moieties to increase delivery of the conjugate into and across one or more intact epithelial or endothelial tissue layers compared to delivery of the compound in the absence of the delivery-enhancing transporter; and
the conjugate has a structure selected from the group consisting of structures 3, 4, 5 and 6, as follows;
wherein;
R1—
X comprises the compound;
X is a functional group on the compound to which the linker is attached;
Y is N or CH;
R2 is hydrogen, alkyl, aryl, acyl, or allyl;
R3 comprises the delivery-enhancing transporter;
R4 is unsubstituted O, substituted N or C or substituted or unsubstituted S;
R5 is OH, SH or NHR6;
R6 is hydrogen, alkyl, aryl, acyl or allyl;
k and m are each independently selected from 1 and 2;
n is 1 to 10; and
Ar is an aryl group having the attached radicals arranged in an ortho or para configuration, which aryl group can be substituted or unsubstituted. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)
-
-
31. A method for enhancing delivery of a compound into and across one or more layers of an animal epithelial and endothelial tissue, the method comprising:
-
contacting the epithelial tissue with a conjugate that comprises the compound and a delivery-enhancing transporter, wherein the delivery-enhancing transporter comprises sufficient guanidino or amidino moieties to increase delivery of the conjugate into and across one or more intact epithelial or endothelial tissue layers compared to delivery of the compound in the absence of the delivery-enhancing transporter; and
wherein the epithelial tissue comprises a blood vessel and the compound enters the blood vessel from the epithelial tissue. - View Dependent Claims (32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)
wherein; R1—
X comprises the compound;
X is a functional group on the compound to which the remainder of the conjugate is attached;
Y is N or CH;
R2 is hydrogen, alkyl, aryl, acyl, or allyl;
R3 comprises the delivery-enhancing transporter;
R4 is unsubstituted O, substituted N or C or substituted or unsubstituted S;
R5 is OH, SH or NHR6;
R6 is hydrogen, alkyl, aryl, acyl or allyl;
k and m are each independently selected from 1 and 2; and
n is 1 to 10; and
Ar is an aryl group having the attached radicals arranged in an ortho or para configuration, which aryl group can be substituted or unsubstituted.
-
-
53. The method of claim 52, wherein X is selected from the group consisting of NH, O, S, and CR7R8, wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.
-
54. The method of claim 52, wherein the conjugate comprises structure 3 and R2 is selected to obtain a conjugate half-life of between 5 minutes and 24 hours.
-
55. The method of claim 52, wherein the conjugate comprises structure 3, Y is N, and R2 is methyl, ethyl, propyl, butyl, allyl, benzyl or phenyl.
-
56. The method of claim 53, wherein R2 is benzyl;
- k, m, and n are each 1, and X is O.
-
57. The method of claim 52, wherein the conjugate comprises structure 4;
- R4 is S;
R5 is NHR6; and
R6 is hydrogen, methyl, allyl, butyl or phenyl.
- R4 is S;
-
58. The method of claim 52, wherein the conjugate comprises structure 4;
- R5 is NHR6;
R6 is hydrogen, methyl, allyl, butyl or phenyl; and
k and m are each 1.
- R5 is NHR6;
-
59. The method of claim 52, wherein the conjugate comprises structure 6 and X is selected from the group consisting of NH, O, S, and CR7R8, wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.
-
60. The method of claim 52, wherein the conjugate comprises structure 6 and R4 is S;
- R5 is NHR6; and
R6 is hydrogen, methyl, allyl, butyl or phenyl.
- R5 is NHR6; and
-
61. A method for enhancing delivery of a compound into and across one or more layers of an animal epithelial or endothelial tissue, the method comprising:
-
contacting the epithelial or endothelial tissue with a conjugate that comprises the compound and a delivery-enhancing transporter, wherein the delivery-enhancing transporter comprises sufficient guanidino or amidino moieties to increase delivery of the conjugate into and across one or more intact epithelial or endothelial tissue layers compared to delivery of the compound in the absence of the delivery-enhancing transporter, and wherein the compound is selected from the group consisting of;
an anti-inflammatory agent, caffeine, proline, salicylic acid, vitamin E;
a therapeutic agent for treating cystic fibrosis, asthma, allergic rhinitis or chronic obstructive pulmonary disease;
a compound that acts in the gastrointestinal epithelium; and
a compound that acts upon immune cells in the dermis. - View Dependent Claims (62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 110)
wherein; R1—
X comprises the compound;
X is a functional group on the compound to which the remainder of the conjugate is attached;
Y is N or CH;
R2 is hydrogen, alkyl, aryl, acyl, or allyl;
R3 comprises the delivery-enhancing transporter;
R4 is unsubstituted O, substituted N or C or substituted or unsubstituted S;
R5 is OH, SH or NHR6;
R6 is hydrogen, alkyl, aryl, acyl or allyl;
k and m are each independently selected from 1 and 2; and
n is 1 to 10; and
Ar is an aryl group having the attached radicals arranged in an ortho or para configuration, which aryl group can be substituted or unsubstituted.
-
-
92. The method of claim 91, wherein X is selected from the group consisting of NH, O, S, and CR7R8, wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.
-
93. The method of claim 91, wherein the conjugate comprises structure 3 and R2 is selected to obtain a conjugate half-life of between 5 minutes and 24 hours.
-
94. The method of claim 91, wherein the conjugate comprises structure 3, Y is N, and R2 is methyl, ethyl, propyl, butyl, allyl, benzyl or phenyl.
-
95. The method of claim 94, wherein R2 is benzyl;
- k, m, and n are each 1, and X is O.
-
96. The method of claim 91, wherein the conjugate comprises structure 4;
- R4 is S;
R5 is NHR6; and
R6 is hydrogen, methyl, allyl, butyl or phenyl.
- R4 is S;
-
97. The method of claim 96, wherein the conjugate comprises structure 4;
- R5 is NHR6;
R6 is hydrogen, methyl, allyl, butyl or phenyl; and
k and m are each 1.
- R5 is NHR6;
-
98. The method of claim 91, wherein the conjugate comprises structure 6 and X is selected from the group consisting of NH, O, S, and CR7R8, wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.
-
99. The method of claim 91, wherein the conjugate comprises structure 6 and R4 is S;
- R5 is NHR6; and
R6 is hydrogen, methyl, allyl, butyl or phenyl.
- R5 is NHR6; and
-
100. The method of claim 61, wherein delivery of the compound into and across the intact epithelial tissue layers is at least two-fold greater than that of the compound conjugated to a basic HIV tat peptide consisting of residues 49-57.
-
101. The method of claim 61, wherein the epithelial tissue is the skin.
-
102. The method of claim 61, wherein the epithelial tissue an eye.
-
103. The method of claim 61, wherein the epithelial tissue a gastrointestinal epithelium.
-
104. The method of claim 61, wherein the epithelial tissue a bronchial epithelium.
-
110. The conjugate of claim 104, wherein R2 is phenyl;
- k, m, and n are each 1, and X is O.
-
105. A method for enhancing delivery of a compound into and across one or more layers of an animal epithelial or endothelial tissue, the method comprising:
-
contacting the epithelial or endothelial tissue with a conjugate that comprises the compound and a delivery-enhancing transporter, wherein the delivery-enhancing transporter comprises sufficient guanidino or amidino moieties to increase delivery of the conjugate into and across one or more intact epithelial or endothelial tissue layers compared to delivery of the compound in the absence of the delivery-enhancing transporter; and
wherein the conjugate is administered topically and the compound is taken up by cells that comprise the follicular or interfollicular epidermis.
-
-
106. A conjugate comprising a) a compound to be delivered into and across one or more layers of an animal epithelial or endothelial tissue, and b) a delivery-enhancing transporter that comprises 5 to 25 arginine residues;
-
wherein the conjugate is substantially stable at acidic pH but the compound is substantially released from the delivery-enhancing transporter at physiological pH. - View Dependent Claims (107, 108, 109, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)
wherein; R1—
X comprises the compound;
X is a functional group on the compound to which the remainder of the conjugate is attached;
Y is N or CH;
R2 is hydrogen, alkyl, aryl, acyl, or allyl;
R3 comprises the delivery-enhancing transporter;
R4 is unsubstituted O, substituted N or C or substituted or unsubstituted S;
R5 is OH, SH or NHR6, R6 is hydrogen, alkyl, aryl, acyl or allyl;
k and m are each independently selected from 1 and 2; and
n is 1 to 10; and
Ar is an aryl group having the attached radicals arranged in an ortho or para configuration, which aryl group can be substituted or unsubstituted.
-
-
108. The conjugate of claim 107, wherein X is selected from the group consisting of NH, O, S, and CR7R8, wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.
-
109. The conjugate of claim 107, wherein the conjugate comprises structure 3, Y is N, and R2 is methyl, ethyl, propyl, butyl, allyl, benzyl or phenyl.
-
111. The conjugate of claim 107, wherein the linker comprises structure 4;
- R4 is S;
R5 is NHR6; and
R6 is hydrogen, methyl, allyl, butyl or phenyl.
- R4 is S;
-
112. The conjugate of claim 107, wherein the conjugate comprises structure 4;
- R5 is NHR6;
R6 is hydrogen, methyl, allyl, butyl or phenyl; and
k and m are each 1.
- R5 is NHR6;
-
113. The conjugate of claim 107, wherein the conjugate comprises:
-
wherein Ph is phenyl.
-
-
114. The conjugate of claim 107, wherein the conjugate comprises structure 6 and X is selected from the group consisting of NH, O, S, and CR7R8, wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.
-
115. The conjugate of claim 107, wherein the conjugate comprises structure 6 and R4 is S;
- R5 is NHR6; and
R6 is hydrogen, methyl, allyl, butyl or phenyl.
- R5 is NHR6; and
-
116. The conjugate of claim 107, wherein the conjugate comprises:
-
117. The conjugate of claim 106, wherein the delivery-enhancing transporter comprises 7 to 15 arginine residues or arginine analogs.
-
118. The conjugate of claim 106, wherein the delivery-enhancing transporter consists essentially of 5 to 50 amino acids, at least 50 percent of which amino acids are arginines or arginine analogs.
-
119. The conjugate of claim 106, wherein the delivery-enhancing transporter comprises at least 5 contiguous arginines or arginine analogs.
-
120. The conjugate of claim 106, wherein the compound is selected from the group consisting of immunosuppressives, antibacterials, antifungals, antivirals, antiproliferatives, hormones, antiinflammatories, vitamins, and analgesics.
-
121. The conjugate of claim 120, wherein the compound is an immunosuppressive.
-
122. The conjugate of claim 121, wherein the immunosuppressive is cyclosporin.
-
123. The conjugate of claim 106, wherein the compound is a glucocorticoid or an ascomycin.
-
124. A method for delivering a conjugate into and across one or more layers of an animal epithelial or endothelial tissue, the method comprising:
-
contacting the epithelial or endothelial tissue with a conjugate wherein the conjugate is structure 8;
wherein T is a delivery-enhancing transporter comprising sufficient guanidino or amidino moieties to increase delivery of the conjugate into and across one or more intact epithelial or endothelial tissue layers compared to delivery of the compound in the absence of the delivery-enhancing transporter. - View Dependent Claims (125, 126, 127, 128, 129, 130, 131, 132, 133, 134)
-
Specification